The Variable Rate Intravenous Insulin Infusion in Clinical Practice 2015: an audit against the new JBDS guidance

Authors

  • Hyma Rachabattula Department of Diabetes, Royal Sussex County Hospital, Eastern Road, Brighton.
  • Emily Simmons Department of Diabetes, Royal Sussex County Hospital, Eastern Road, Brighton.
  • Sonya Ghatahora Department of Diabetes, Royal Sussex County Hospital, Eastern Road, Brighton.
  • Paul Grant Department of Diabetes, Royal Sussex County Hospital, Eastern Road, Brighton. Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford.

DOI:

https://doi.org/10.15277/bjd.2016.059

Keywords:

insulin sliding scale, VRIII, JBDS, insulin safety

Abstract

Background: Variable rate intravenous insulin infusion (VRIII) is an established method to achieve normoglycaemia in unwell or fasting patients. The Joint British Diabetes Societies (JBDS) released new guidance for the use of VRIII in medical inpatients in October 2014. This specifies the appropriate clinical circumstances in which a VRIII should be used and how it should be initiated, managed and discontinued safely.

Methods: We developed an audit tool based on the guidelines and audited the current practice at the Royal Sussex County Hospital, Brighton, prior to the roll out of the new standards. We have audited 50 patients on VRIII under non-specialist medical and surgical care.

Results: Several parameters were checked. VRIII prescription was signed appropriately as per the guidance in 98% of patients. Oral hypoglycaemic medications were omitted in 83%. Short-acting and mix insulins were omitted only in 88%. Long-acting insulin was administered only in 77% of the patients. Blood glucose was tested 1–2 hourly in 90% of patients. All patients with hypoglycaemic episodes were treated as per protocol. On the occasions where VRIII was discontinued, it was reinitiated within 20 min as per the guidelines only in 36% of cases. In patients with persistent hyperglycaemia, the rate was increased in 80% of cases.

Discussion: Clinical practice surrounding the use, appropriate management and monitoring parameters appeared to fall short of the standards suggested by the latest JBDS guidance. Our audit outcome was to prepare a protocol for the trust summarising the indications for VRIII, target capillary blood glucose, how and when to stop VRIII for patients with diabetes and also a prompt to prescribe basal insulin for patients with diabetes and when a referral should be made to the diabetes inpatient team. Introducing teaching sessions to all the professionals and raising the awareness through a hospital communication programme on the wards would also help to theoretically improve the results.

Conclusions: The majority of patients on VRIII are managed by non-diabetic teams and practice may vary from set guidance due to unfamiliarity and lack of diabetes specific knowledge. The appropriate use of VRIII needs to be tackled through remedial education, introduction of the new JBDS guidance and allied to improvements in systems and processes.

References

Umpierrez G, Isaacs S, Bazargan N. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87(3):978-82. http://dx.doi.org/10.1210/jc.2014-3415

Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978;1(6107):204-07. http://dx.doi.org/10.1136/bmj.1.6107.204

Bruno A, Gregori D, Caropreso A. Normal glucose values are associated with a lower risk of mortality in hospitalized patients. Diabetes Care 2008;31(11):2209-10. http://dx.doi.org/10.2337/dc08-0672

Montori V, Bistrian B, McMahon M. Hyperglycemia in acutely ill patients. JAMA 2002;288:2167-9. http://dx.doi.org/10.1001/jama.288.17.2167

National Diabetes Inpatient Audit. http://www.hscic.gov.uk/diabetesinpatientaudit (accessed 14 July 2015).

George S, Dale J, Stanisstreet D, et al. A guideline for the use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. Br J Diabetes Vasc Dis 2015;15:82-5. http://dx.doi.org/10.15277/bjdvd.2015.014

Cheung N, Wong V, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study; a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006;29(4): 765-70. http://dx.doi.org/10.2337/diacare.29.04.06.dc05-1894

Pomposelli J, Baxter J, Babineau T, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr 1998;22(2):77-81. http://dx.doi.org/10.1177/014860719802200277

Capes S, Hunt D, Malmberg K. Stress hyperglycemia and prognosis of stroke in non-diabetic and diabetic patients: a systematic overview. Stroke 2001;32(10):2426-32. http://dx.doi.org/10.1161/hs1001.096194

Grant P, Morel K, Lambert V, Burberry A, Vaughan N. Diabetes direct: solutions for inpatients with diabetes. Diabet Med 2015;32(Suppl 1):162-3.

Grant P. A multi-system approach to reducing insulin errors. Clinical Risk 2011;17(5):180-7. http://dx.doi.org/10.1258/cr.2011.011005

Grant P, Mustafa O, Malik R. Setting up an insulin safety group: a practical approach. Pract Diabetes 2012;29(4):160-2. http://dx.doi.org/10.1002/pdi.1682

Downloads

Published

2016-03-08

Issue

Section

Learning from practice